Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desnitroimidacloprid SCHEMBL10465062 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| Desnitroimidacloprid SCHEMBL8637512 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL7496995 | 0.93 | CHRNA1 (0.63) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL20572266 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL21382443 | 0.83 | ALDH1A1 (0.62) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL7999218 | 0.82 | CYP11B1 (0.47) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL12704680 | 0.82 | ALDH1A1 (0.57) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL7992725 | 0.82 | CYP11B1 (0.47) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL7981584 | 0.82 | CHRM1 (0.43) | SMN1; SMN2CHRNA1CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL24709610 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746397-B | Method for synthesizing imidacloprid with high yield | 江苏扬农化工集团有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-110818686-B | Synthetic method of imidacloprid | 江苏扬农化工集团有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-110818686-A | Synthetic method of imidacloprid | 江苏扬农化工集团有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-110746397-A | Method for synthesizing imidacloprid with high yield | 江苏扬农化工集团有限公司 | 2020-02-04 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | claimed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | claimed |
| US-20250382211-A1 | BIOLOGICALLY INOCULATED SORPTIVE BEAD MEDIA | UNIV IOWA RES FOUND (US) | 2025-12-18 | — | — | US | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-5428032-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1995-06-27 | — | — | US | disclosed |
| US-5298507-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1994-03-29 | — | — | US | disclosed |
| US-5204360-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5001138-A | Insecticides | NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) | 1991-03-19 | — | — | US | disclosed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | CHRNA2, CHRNA7, CHRNB2 | SMN1; SMN2 755/4885CHRNA1 6/4885CHRNA7 2/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | SMN1; SMN2 1861/4885CHRNA1 2649/4885CHRNA7 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.